GlycoVaxyn’s First Clinical Study with Bioconjugate Vaccine Initiated
Study to Evaluate Safety, Reactogenicity and Immunogenicity of Vaccine Against Shigella dysenteriae
25-Feb-2010 -
GlycoVaxyn has commenced a Phase I clinical study with its vaccine candidate (GVXN SD133) against Shigella dysenteriae, a cause of serious intestinal infections. This is the first product from the company to enter clinical evaluation.
The objective of this single-blind, first in human study is ...
bacterial infections
Carrier
clinical trials
+6